Clinical effect of preoperative high-dose atorvastatin against no-reflow after pci

Experimental and Therapeutic Medicine

Volumn 13, Issue 1, 2017, Pages 97-102

  Liu, Wenbo ^a   Zou, Zhipeng ^b   Jiang, Haipeng ^b   Li, Qiang ^a   Guo, Fangming ^a   Wang, Zhen ^a   Zhu, Hongguang ^b  

^a YANTAISHAN HOSPITAL   (China)

^b Haigang Hospital of Yantai   (China)

Author keywords

Acute coronary syndrome; Atorvastatin; Cardiac remodeling; Emergency percutaneous coronary intervention

Indexed keywords

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE; CREATINE KINASE MB; GLYCERYL TRINITRATE; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ASPIRATION CATHETER; BEDTIME DOSAGE; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIZZINESS; DOPPLER FLOWMETRY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE PERFUSION; HEART PALPITATION; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NO REFLOW PHENOMENON; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRECORDIAL PAIN; PREOPERATIVE PERIOD; RESTENOSIS; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOEMBOLISM;

EID: 85006036388     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3910     Document Type: Article

References (24)

1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, et al; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Biomarker Subcommittee; ECG Subcommittee; Imaging Subcommittee; Classification Subcommittee; Intervention Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; ESC Committee for Practice Guidelines (CPG); Document Reviewers: Third universal definition of myocardial infarction. J Am Coll Cardiol 60: 1581-1598, 2012.
2. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, et al: ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 36: 970-1062, 2000.
3. Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P and Kinlay S; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators: Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc 2: e003103, 2013.
4. Abdelmouttaleb I, Danchin N, Ilardo C, Aimone-Gastin I, Angioï M, Lozniewski A, Loubinoux J, Le Faou A and Guéant JL: C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 137: 346-351, 1999.
5. Zhao XJ, Liu XL, He GX and Xu HP: Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion. Braz J Med Biol Res 47: 245-251, 2014.
6. Zhao B, Li J, Luo X, Zhou Q, Chen H and Shi H: The role of von Willebrand factor and ADAMTS13 in the no-reflow phenomenon: After primary percutaneous coronary intervention. Tex Heart Inst J 38: 516-522, 2011.
7. Zhou SS, Tian F, Chen YD, Wang J, Sun ZJ, Guo J and Jin QH: Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction. J Geriatr Cardiol 12: 135-142, 2015.
8. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA and Blasetto JW; STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92: 152-160, 2003.
9. Wang JW, Chen YD, Wang CH, Yang XC, Zhu XL and Zhou ZQ: Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Cardiology 124: 153-160, 2013.
10. Zhou H, He XY, Zhuang SW, Wang J, Lai Y, Qi WG, Yao YA and Liu XB: Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention. World J Emerg Med 5: 96-102, 2014.
11. Qi K, Li L, Li X, Zhao J, Wang Y, You S, Hu F, Zhang H, Cheng Y, Kang S, et al: Cardiac microvascular barrier function mediates the protection of Tongxinluo against myocardial ischemia/reperfusion injury. PLoS One 10: e0119846, 2015.
12. Uitterdijk A, Yetgin T, te Lintel Hekkert M, Sneep S, Krabbendam-Peters I, van Beusekom HM, Fischer TM, Cornelussen RN, Manintveld OC, Merkus D, et al: Vagal nerve stimulation started just prior to reperfusion limits infarct size and no-reflow. Basic Res Cardiol 110: 51, 2015.
13. Ahn SJ, Park KH, Ryoo NK, Hong JH, Jung C, Yoon CH, Han MK and Woo SJ: No-reflow phenomenon in central retinal artery occlusion: incidence, risk factors, and clinical implications. PLoS One 10: e0142852, 2015.
14. Shen Y, Wu H, Wang C, Shao H, Huang H, Jing H and Li D: Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor γ. Eur J Pharmacol 649: 255-262, 2010.
15. Stumpf C, Petzi S, Seybold K, Wasmeier G, Arnold M, Raaz D, Yilmaz A, Daniel WG and Garlichs CD: Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin Sci (Lond) 116: 45-52, 2009.
16. Małek LA, Śpiewak M, Kłopotowski M, Miśko J, Rużyłło W and Witkowski A: The size does not matter - the presence of microvascular obstruction but not its extent corresponds to larger infarct size in reperfused STEMI. Eur J Radiol 81: 2839-2843, 2012.
17. Maksimenko AV and Turashev AD: No-reflow phenomenon and endothelial glycocalyx of microcirculation. Biochem Res Int 2012: 859231, 2012.
18. Wang CH, Chen YD, Yang XC, Wang LF, Wang HS, Sun ZJ and Liu HB: A no-reflow prediction model in patients with ST-elevation acute myocardial infarction and primary drug eluting stenting. Scand Cardiovasc J 45: 98-104, 2011.
19. Lee MG, Jeong MH, Ahn Y, Cho JG, Park JC, Kang JC, Chae SC, Hur SH, Hong TJ, Kim YJ, et al; Korea Acute Myocardial Infarction Registry Investigators: Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome. Circ J 75: 2120-2127, 2011.
20. Choi YH, Suh SH, Choi JS, Kim CS, Sim DS, Bae EH, Lim SY, Ma SK, Jeong MH and Kim SW; Korea Acute Myocardial Infarction Registry Investigators: Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction. Circ J 76: 2405-2411, 2012.
21. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G and Montinaro A: Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 54: 558-565, 2009.
22. Aung Naing K, Li L, Su Q and Wu T: Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev 6: CD009503, 2013.
23. Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ and Egido J: 3-Hydroxy-3-methyl-glutaryl coenzyme a reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho a prenylation. Atherosclerosis 161: 17-26-2002.
24. Clearfield M: Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Curr Atheroscler Rep 12: 8-10, 2010.